Vector Borne Diseases: Clinical Trials

23 trials for Vector Borne Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 terminated. 23 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 123Terminated 23
Phase 24Terminated 4

Follow Vector Borne Diseases: new trials by email Literature Review of Vector Borne Diseases trials Research Report on Vector Borne Diseases

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults
Oleylphosphocholine - Leishmaniasis
Phase 1TerminatedUniversity Hospital Tuebingen132023-06-212024-03-12
A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI
PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline - Malaria, Malaria,Falciparum
Phase 1TerminatedSanaria Inc.312022-12-062024-11-25
Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model
AT-752, Placebo Comparator - Dengue
Phase 1TerminatedAtea Pharmaceuticals, Inc.52022-04-222023-04-21
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
AWZ1066S, Placebo - Filariasis, Lymphatic, Onchocerciasis
Phase 1TerminatedLiverpool School of Tropical Medicine302021-12-102023-09-21
Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.
Pfs25-IMX313 (10ug)/Matrix-M (50ug), Pfs25-IMX313 (50ug)/Matrix-M (50ug), Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug) - Malaria,Falciparum
Phase 1TerminatedUniversity of Oxford342021-05-252025-01-27
Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants
GSK3494245, Placebo - Leishmaniasis
Phase 1TerminatedGlaxoSmithKline592020-09-292026-05-01
A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19
Galidesivir, Placebo - COVID-19, Yellow Fever
Phase 1TerminatedBioCryst Pharmaceuticals242020-04-092021-05-27
VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine
Pfs25-IMX313/Matrix-M1 - Malaria,Falciparum
Phase 1TerminatedUniversity of Oxford12019-09-272020-09-29
Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects
GSK3186899, Placebo - Leishmaniasis
Phase 1TerminatedGlaxoSmithKline252019-04-302023-02-27
Safety and Pharmacokinetics Study of DM1157 to Treat Malaria
DM1157, Placebo - Malaria
Phase 1TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)502018-07-312021-07-23
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution - Viral Infection
Phase 1TerminatedEmergent BioSolutions72016-05-272024-03-18
A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
DSM265, OZ439 - Malaria
Phase 1 / Phase 2TerminatedMedicines for Malaria Venture162015-10-012020-06-05
Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos
KAE609, Piperaquine Phosphate - Plasmodium Falciparum Malaria
Phase 1TerminatedNovartis Pharmaceuticals82015-07-012019-07-23
MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants
MMV390048 20mg - Malaria, Falciparum
Phase 1TerminatedMedicines for Malaria Venture62014-10-012020-06-09
Safety, Tolerability & Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers
OZ439 100mg, OZ439 400mg, MQ 250 mg, single dose - Malaria
Phase 1TerminatedMedicines for Malaria Venture252012-08-012015-04-16
Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food
Tablets Fexinidazole, Placebo - Trypanosomiasis, African
Phase 1TerminatedDrugs for Neglected Diseases302011-09-012017-03-31
Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria
Sevuparin sodium + atovaquone/proquanil, atovaquone/proquanil - Malaria, Falciparum
Phase 1 / Phase 2TerminatedModus Therapeutics AB532011-09-012014-08-19
Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine
p52-/p36- GAP Vaccine, p52-p36- GAP Vaccine - Malaria
Phase 1 / Phase 2TerminatedSeattle Children's Hospital62010-03-012019-10-28
A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria
GSK932121; Rosiglitazone; Rosuvastatin - Malaria
Phase 1TerminatedGlaxoSmithKline122008-12-112017-08-03
Chlorproguanil-Dapsone in Pregnant Women
chlorproguanil-dapsone - Malaria
Phase 1TerminatedCenters for Disease Control and Prevention1322005-07-012025-04-20

Showing 20 of 23. Sign in to see all of them.

Narrower conditions

Malaria (9)  ·  Malaria, Falciparum (8)  ·  Leishmaniasis (3)  ·  Dengue (2)  ·  Arbovirus Infections (1)  ·  COVID-19 (1)  ·  Elephantiasis, Filarial (1)  ·  Flaviviridae Infections (1)  ·  Flavivirus Infections (1)  ·  Hemorrhagic Fevers, Viral (1)  ·  Leishmaniasis, Visceral (1)  ·  Onchocerciasis (1)  ·  RNA Virus Infections (1)  ·  Trypanosomiasis, African (1)  ·  Virus Diseases (1)

Broader conditions

Infections (23)  ·  Parasitic Diseases (19)  ·  Mosquito-Borne Diseases (18)  ·  Protozoan Infections (18)  ·  Euglenozoa Infections (5)  ·  Malaria (4)  ·  Skin Diseases (4)  ·  Skin Diseases, Infectious (4)  ·  Skin Diseases, Parasitic (4)  ·  Skin and Connective Tissue Diseases (4)  ·  Arbovirus Infections (3)  ·  Flaviviridae Infections (3)  ·  Flavivirus Infections (3)  ·  RNA Virus Infections (3)

Interventions

Matrix-M (2)  ·  artefenomel (2)  ·  AT-752 (1)  ·  Atovaquone (1)  ·  DSM265 (1)  ·  GSK3186899 (1)  ·  MMV390048 (1)  ·  Malaria Vaccines (1)  ·  NITD 609 (1)  ·  Rosiglitazone (1)  ·  Rosuvastatin Calcium (1)  ·  Saline Solution (1)  ·  Solutions (1)  ·  chloroguanil, dapsone drug combination (1)  ·  fexinidazole (1)

Sponsors

GlaxoSmithKline (3)  ·  Medicines for Malaria Venture (3)  ·  University of Oxford (2)  ·  AB Foundation (1)  ·  Atea Pharmaceuticals, Inc. (1)  ·  BioCryst Pharmaceuticals (1)  ·  Centers for Disease Control and Prevention (1)  ·  Drugs for Neglected Diseases (1)  ·  Emergent BioSolutions (1)  ·  Liverpool School of Tropical Medicine (1)  ·  Modus Therapeutics AB (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Novartis Pharmaceuticals (1)  ·  Sanaria Inc. (1)  ·  Sarepta Therapeutics, Inc. (1)

Countries

United States (5)  ·  Australia (4)  ·  United Kingdom (4)  ·  Brazil (2)  ·  France (1)  ·  Germany (1)  ·  Mali (1)  ·  South Africa (1)  ·  Tanzania (1)  ·  Thailand (1)

Top investigators

Angela Minassian (1)  ·  Angela Minassian, PhD (1)  ·  Anna Leitgeb, PhD (1)  ·  Blaise Genton, MD PhD (1)  ·  Esper Kallas, MD, PhD (1)  ·  Feiko ter Kuile, MD, PhD (1)  ·  Graham Devereux, MD (1)  ·  James McCarthy, Dr. (1)  ·  James McCarthy, MD FRACP (1)  ·  James McCarthy, Prof (1)  ·  Karen I Barnes (1)  ·  Kassoum Kayentao, MD, MSPH (1)  ·  Kirsten E Lyke, MD (1)  ·  Lionel Hovsepian, MD (1)

Results publications

PMID 17925866, PMID 18060072, PMID 24029408, PMID 27930660, PMID 29244851, PMID 30858218, PMID 31932368, PMID 32479608, PMID 33199389, PMID 34179977, PMID 35184256, PMID 38924387, PMID 40098097, PMID 42127151

NIH funding

2019 (1), 272201300017C-18-0-1 (1), U44AI167783 (1)